Tumor mutational burden measurement using comprehensive genomic profiling assay.
Sign Up to like & getrecommendations! Published in 2022 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyac063
Abstract: BACKGROUND Tumors with a high number of mutations in the genome, or tumor mutational burden, are presumed to be more likely to respond to immune checkpoint inhibitors. However, the optimal method to calculate tumor mutational… read more here.
Keywords: mutational burden; tumor mutational; deoxyribonucleic acid; todai oncopanel ... See more keywords
Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Science"
DOI: 10.1111/cas.15717
Abstract: Comprehensive cancer genome profiling (CGP) has been nationally reimbursed in Japan since June 2019. Less than 10% of the patients have been reported to undergo recommended treatment. Todai OncoPanel (TOP) is a dual DNA–RNA panel… read more here.
Keywords: comprehensive cancer; todai oncopanel; treatment; cancer ... See more keywords